Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis
Go back to Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1211.15 -20.79 (1.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1231.94 | 52 Week High | $88.16 | |||
| Open | $1230.65 | 52 Week Low | $67.88 | |||
| Day High | $1238.00 | P/E | 280.36 | |||
| Day Low | $1210.01 | EPS | $4.32 | |||
| Volume | 1,390,968 | |||||
